Literature DB >> 30714128

Low-dose lenalidomide maintenance after induction therapy in older patients with primary central nervous system lymphoma.

Khoan Vu1, Gabriel Mannis1,2, Jimmy Hwang2,3, Huimin Geng2,4, James L Rubenstein1,2,5.   

Abstract

Entities:  

Keywords:  zzm321990primary central nervous system lymphomazzm321990; immunosenescence; immunotherapy; lenalidomide; lymphoma

Mesh：

Substances：

Year:  2019        PMID： 30714128      PMCID： PMC8776513          DOI： 10.1111/bjh.15787

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  10 in total

Review 1.  Challenges in the treatment of elderly patients with primary central nervous system lymphoma.

Authors:  Patrick Roth; Khê Hoang-Xuan
Journal:  Curr Opin Neurol       Date:  2014-12       Impact factor: 5.710

2.  Introduction to a review series on hematologic disease at older age.

Authors:  Bob Löwenberg
Journal:  Blood       Date:  2017-11-15       Impact factor: 22.113

3.  The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades.

Authors:  Joe S Mendez; Quinn T Ostrom; Haley Gittleman; Carol Kruchko; Lisa M DeAngelis; Jill S Barnholtz-Sloan; Christian Grommes
Journal:  Neuro Oncol       Date:  2018-04-09       Impact factor: 12.300

4.  Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma.

Authors:  James L Rubenstein; Huimin Geng; Eleanor J Fraser; Paul Formaker; Lingjing Chen; Jigyasa Sharma; Phoebe Killea; Kaylee Choi; Jenny Ventura; John Kurhanewicz; Clifford Lowell; Jimmy Hwang; Patrick Treseler; Penny K Sneed; Jing Li; Xiaomin Wang; Nianhang Chen; Jon Gangoiti; Pamela N Munster; Bertil Damato
Journal:  Blood Adv       Date:  2018-07-10

5.  Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial.

Authors:  Antonio Omuro; Olivier Chinot; Luc Taillandier; Hervé Ghesquieres; Carole Soussain; Vincent Delwail; Thierry Lamy; Rémy Gressin; Sylvain Choquet; Pierre Soubeyran; Aymeri Huchet; Alexandra Benouaich-Amiel; Sophie Lebouvier-Sadot; Emmanuel Gyan; Valérie Touitou; Maryline Barrié; Monica Sierra del Rio; Alberto Gonzalez-Aguilar; Caroline Houillier; Daniel Delgadillo; Lucette Lacomblez; Marie Laure Tanguy; Khê Hoang-Xuan
Journal:  Lancet Haematol       Date:  2015-06-03       Impact factor: 18.959

6.  Preferential enhancement of older human T cell cytokine generation, chemotaxis, proliferation and survival by lenalidomide.

Authors:  Mei-Chuan Huang; Nigel H Greig; Weiming Luo; David Tweedie; Janice B Schwartz; Dan L Longo; Luigi Ferrucci; William B Ershler; Edward J Goetzl
Journal:  Clin Immunol       Date:  2010-12-03       Impact factor: 3.969

7.  High-dose methotrexate for elderly patients with primary CNS lymphoma.

Authors:  Jay-Jiguang Zhu; Elizabeth R Gerstner; David A Engler; Maciej M Mrugala; Whitney Nugent; Kristin Nierenberg; Fred H Hochberg; Rebecca A Betensky; Tracy T Batchelor
Journal:  Neuro Oncol       Date:  2008-08-29       Impact factor: 12.300

8.  Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center.

Authors:  Mary R Welch; Antonio Omuro; Lisa M Deangelis
Journal:  Neuro Oncol       Date:  2012-09-05       Impact factor: 12.300

9.  Age, gender, and racial differences in incidence and survival in primary CNS lymphoma.

Authors:  J L Villano; M Koshy; H Shaikh; T A Dolecek; B J McCarthy
Journal:  Br J Cancer       Date:  2011-09-13       Impact factor: 7.640

10.  High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study).

Authors:  K Fritsch; B Kasenda; E Schorb; P Hau; J Bloehdorn; R Möhle; S Löw; M Binder; J Atta; U Keller; H-H Wolf; S W Krause; G Heß; R Naumann; S Sasse; C Hirt; M Lamprecht; U Martens; A Morgner; J Panse; N Frickhofen; A Röth; C Hader; M Deckert; H Fricker; G Ihorst; J Finke; G Illerhaus
Journal:  Leukemia       Date:  2016-11-15       Impact factor: 11.528
  10 in total
  9 in total

Review 1.  Central Nervous System Lymphoma: Novel Therapies.

Authors:  Shannon P Fortin Ensign; Diamone Gathers; Julia Erin Wiedmeier; Maciej M Mrugala
Journal:  Curr Treat Options Oncol       Date:  2022-02-19

2.  Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial.

Authors:  Andrés J M Ferreri; Teresa Calimeri; Maurilio Ponzoni; Flavio Curnis; Gian Marco Conte; Eloise Scarano; Eltjona Rrapaj; Daniela De Lorenzo; Dario Cattaneo; Federico Fallanca; Alessandro Nonis; Marco Foppoli; Paolo Lopedote; Giovanni Citterio; Letterio S Politi; Marianna Sassone; Piera Angelillo; Elena Guggiari; Sara Steffanoni; Vittoria Tarantino; Fabio Ciceri; Claudio Bordignon; Nicoletta Anzalone; Angelo Corti
Journal:  Blood Adv       Date:  2020-08-11

3.  Maintenance lenalidomide in primary CNS lymphoma.

Authors:  J L Rubenstein; H Geng; K Vu; G Mannis; P Formaker; J Hwang; P N Munster; B Damato
Journal:  Ann Oncol       Date:  2019-08-01       Impact factor: 32.976

4.  Diagnosis, prognosis and treatment of primary central nervous system lymphoma in the elderly population (Review).

Authors:  Yanxia Liu; Qingmin Yao; Feng Zhang
Journal:  Int J Oncol       Date:  2021-02-01       Impact factor: 5.650

Review 5.  Current and emerging therapies for primary central nervous system lymphoma.

Authors:  Yan Yuan; Tianling Ding; Shu Wang; Hong Chen; Ying Mao; Tong Chen
Journal:  Biomark Res       Date:  2021-05-06

Review 6.  Novel insights into the biomarkers and therapies for primary central nervous system lymphoma.

Authors:  Yujia Zhai; Xiangxiang Zhou; Xin Wang
Journal:  Ther Adv Med Oncol       Date:  2022-05-04       Impact factor: 5.485

7.  Secondary CNS myeloma with remission after systemic CNS-penetrating agents.

Authors:  Luis G Fernandez; Daniel Eduardo Oyon; Vinai Gondi; Sean Grimm; Osaama H Khan
Journal:  Neurooncol Adv       Date:  2022-07-01

8.  Primary central nervous system lymphoma in older adults and the rationale for maintenance strategies: a narrative review.

Authors:  Mazie Tsang; James L Rubenstein; Elisa Jacobsen Pulczynski
Journal:  Ann Lymphoma       Date:  2021-09-30

Review 9.  On point in primary CNS lymphoma.

Authors:  Mazie Tsang; Joseph Cleveland; James L Rubenstein
Journal:  Hematol Oncol       Date:  2020-07-03       Impact factor: 5.271
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.